Ratio Review: Analyzing Lexeo Therapeutics Inc (LXEO)’s Price-to-Cash and Price-to-Free Cash Flow

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

After finishing at $4.10 in the prior trading day, Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $3.47, down -15.37%. In other words, the price has decreased by -$15.37 from its previous closing price. On the day, 0.54 million shares were traded. LXEO stock price reached its highest trading level at $3.9 during the session, while it also had its lowest trading level at $3.45.

Ratios:

Our goal is to gain a better understanding of LXEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.52 and its Current Ratio is at 5.52. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on June 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $28.

On June 06, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $22.

On November 28, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $20.Stifel initiated its Buy rating on November 28, 2023, with a $20 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 19 ’25 when Townsend Richard Nolan sold 4,326 shares for $4.41 per share. The transaction valued at 19,091 led to the insider holds 220,119 shares of the business.

See Tai Sandi sold 1,486 shares of LXEO for $6,558 on Feb 19 ’25. The Chief Development Officer now owns 53,889 shares after completing the transaction at $4.41 per share. On Feb 19 ’25, another insider, Adler Eric, who serves as the Chief Medical Officer of the company, sold 2,359 shares for $4.41 each. As a result, the insider received 10,410 and left with 68,266 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 136698576 and an Enterprise Value of 3599579.

Stock Price History:

The Beta on a monthly basis for LXEO is 0.46, which has changed by -0.76232874 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $19.50, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is -13.83%, while the 200-Day Moving Average is calculated to be -59.90%.

Shares Statistics:

The stock has traded on average 495.95K shares per day over the past 3-months and 1267980 shares per day over the last 10 days, according to various share statistics. A total of 33.07M shares are outstanding, with a floating share count of 25.03M. Insiders hold about 24.61% of the company’s shares, while institutions hold 83.16% stake in the company. Shares short for LXEO as of 1741910400 were 2215452 with a Short Ratio of 4.47, compared to 1739491200 on 2310952. Therefore, it implies a Short% of Shares Outstanding of 2215452 and a Short% of Float of 7.489999999999999.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Most Popular